Serena Williams’ Super Bowl ad for Ro, where she injects a GLP-1 drug on national television, has fueled intense debate over pharmaceutical marketing and celebrity endorsements in health, drawing both praise for destigmatizing weight management and sharp criticism for potentially influencing young viewers. The 30-second commercial, aired during the first half of Super Bowl LX on February 8, 2026, at Levi’s Stadium in Santa Clara, California, features the 44-year-old tennis icon confidently showcasing her 34-pound weight loss journey while promoting Ro’s telehealth platform for accessing GLP-1 medications. With over 100 million viewers tuned in, the spot quickly amassed millions of social media impressions, highlighting Williams’ personal health gains like a 30 percent cholesterol drop and reduced heart disease risk, but also igniting backlash over the normalization of injectable drugs during a family event.
The ad opens with Williams declaring “I’m on Ro” as she poses on a futuristic blue platform, her curly blonde hair flowing and body clad in a light blue asymmetrical one-shoulder crop top paired with a pleated miniskirt, emphasizing her toned physique through energetic dance moves captured in wide, overhead, and close-up angles. Subtitles flash her achievements: “34 pounds down” with a downward arrow graphic, “On GLP-1s” as she flexes, and “Healthier on Ro” overlaying app interfaces showing doctor chats and support features. A key moment shows a macro shot of her administering the injection to her arm, followed by “On Ro FDA approved GLP-1” (noting a subtitle typo listing it as GLP-2), and introducing the pill form with “Now even in a pill.” The commercial builds to her jumping and posing triumphantly, with lines like “Weight loss expertise I trust,” “I’m moving better on Ro,” and “I’m feeling better on Ro,” all set to an upbeat electronic soundtrack in bright, ethereal blue lighting that conveys empowerment and vitality. This visual narrative promotes Ro’s app-based service, where users can consult virtually, get prescriptions for GLP-1 agonists like semaglutide (branded as Wegovy or Ozempic) or tirzepatide (Zepbound), and have them delivered or picked up at pharmacies, targeting adults with obesity or overweight conditions seeking medically supervised weight loss alongside diet and exercise.
GLP-1 agonists, the core product in the ad, mimic a hormone that regulates blood sugar and appetite, leading to average weight reductions of 14 to 20 percent over a year when combined with lifestyle changes, as Williams credits for her stabilized blood sugar, less knee stress, and overall improved mobility post-pregnancy. Ro positions these as accessible tools for broader health benefits, with pricing starting at $199 per month for the first two months on injections, rising to $349 thereafter, or $149 to $299 for pills depending on dose, often covered partially by insurance but available cash-pay via the app. However, side effects remain a critical concern not addressed in the ad; common issues include nausea, vomiting, diarrhea, constipation, loss of appetite, and abdominal pain, typically worsening at dose increases but manageable for many. More serious risks involve pancreatitis, gallbladder problems, delayed gastric emptying increasing anesthesia complications, and “Ozempic face”—sagging skin, wrinkles, and hollowed features from rapid fat loss—prompting experts to recommend gradual dosing and monitoring. Williams’ ambassadorship, announced in August 2025, ties into her husband Alexis Ohanian’s role as a Ro investor and board member, adding layers to the promotion’s perceived authenticity.
While exact compensation for Williams remains undisclosed, the ad’s production and airtime represent a significant investment, with Super Bowl slots averaging $8 million for 30 seconds, underscoring Ro’s bet on high-profile endorsements to expand GLP-1 access amid surging demand. Public sentiment on platforms like X leaned negative, with over 3.8 million views on a viral clip and comments decrying it as “disgusting” for glamorizing drugs to children or questioning an athlete’s reliance on medication. Other relevant patient stories in the campaign, like Charles Barkley’s 45-pound loss or everyday users gaining energy for marathons, aim to broaden appeal, but critics highlight the ad’s focus on positives without balancing risks, especially given Williams’ $350 million net worth and influence as a 23-time Grand Slam champion who has faced body-shaming in her career.
This ad marks a pivotal moment in how health tech companies like Ro leverage celebrity narratives to shift perceptions of GLP-1s from vanity aids to essential wellness tools, yet it raises ethical questions about direct-to-consumer advertising in prime-time slots. By centering Williams’ story of reclaiming strength after motherhood, the campaign empowers those struggling with weight-related health issues, but overlooking side effects and potential long-term dependencies could mislead viewers, emphasizing the industry’s responsibility for transparent education. As GLP-1 use grows, such promotions might drive more informed discussions, but they also spotlight the fine line between inspiration and commercialization in public health.
For safety details on GLP-1 medications, consult the FDA’s guidance. View the full ad on Ro’s site. Learn about Super Bowl LX via Wikipedia. Williams’ journey is detailed on her Instagram.
